The Evaluation of User Experience With FARAVIEW™ Technology of the OPAL HDx™ Mapping System When Used With the FARAWAVE NAV™ ULTRA Pulsed Field Ablation Catheter in the Treatment of Atrial Fibrillation

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.

Also called NCT07925359

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07925359
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Croatia, Czechia, France (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07925359. Allocation not applicable; no masking; primary purpose treatment. Start 2027-01-20 (anticipated); primary completion 2027-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Evaluation of User Experience With FARAVIEW™ Technology of the OPAL HDx™ Mapping System When Used With the FARAWAVE NAV™ ULTRA Pulsed Field Ablation Catheter in the Treatment of Atrial Fibrillation
Acronym
NAVigate-ULTRA
Condition
Atrial Fibrillation (AF)
Condition
Paroxysmal AF
Condition
Persistent Atrial Fibrillation (PersAF)
Condition
FARAPULSE
Intervention (Device)
Ablation Treatment with FARAPULSE™ Pulsed Field Ablation (PFA) System and OPAL HDx™ Mapping System
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct07925359
Content hash
abb3ce7cc3922f6ccbca921c089f2dd937390d116eea5c322b564c870c4cc3a8